🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07536867
Starting soon Not applicable

Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block in Patients Undergoing Breast Cancer Surgery

NCT07536867 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-08-30
Last updated
2026-05-11

Condition(s) studied

Breast CancerLymph Node DissectionPostoperative PainMastectomy

Investigational drug(s) / intervention(s)

Serratus posterior superior intercostal plane blockRhomboid intercostal plane block

Serratus posterior superior intercostal plane block: Ultrasound-guided serratus posterior superior intercostal plane block (SPSIPB) performed at the upper thoracic level for postoperative analgesia following breast cancer surgery.

Rhomboid intercostal plane block: Ultrasound-guided rhomboid intercostal block (RIB) performed for postoperative analgesia following breast cancer surgery.

Study summary

This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Rhomboid Intercostal Block in patients undergoing Breast Cancer Surgery With Axillary Lymph Node Dissection. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Female patients aged 18-65 years * ASA physical status I-III * Scheduled for elective breast cancer surgery with axillary lymph node dissection * Body mass index (BMI) between 18 and 35 kg/m² * Ability to understand and use the patient-controlled analgesia (PCA) device * Ability to provide written informed consent Exclusion Criteria: * Refusal to participate * Allergy to local anesthetics * Infection at the injection site * Coagulopathy or ongoing anticoagulant therapy * Chronic opioid use or opioid dependence * Severe hepatic or renal insufficiency * Pregnancy or breastfeeding * Cognitive impairment or inability to communicate pain scores * Body mass index (BMI) \<18 or \>35 kg/m²

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Antalya City Hospital Antalya Turkey (Türkiye)

More Antalya City Hospital trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07536867 on ClinicalTrials.gov ↗ ← All trials in Turkey